Home >> Research Area >> BIBF 1202

BIBF 1202

VEGFR/PDGFR/FGFR inhibitor CAS# 894783-71-2

BIBF 1202

Catalog No. BCC5298----Order now to get a substantial discount!

Product Name & Size Price Stock
BIBF 1202: 5mg $863 In Stock
BIBF 1202: 10mg Please Inquire In Stock
BIBF 1202: 20mg Please Inquire Please Inquire
BIBF 1202: 50mg Please Inquire Please Inquire
BIBF 1202: 100mg Please Inquire Please Inquire
BIBF 1202: 200mg Please Inquire Please Inquire
BIBF 1202: 500mg Please Inquire Please Inquire
BIBF 1202: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of BIBF 1202

Number of papers citing our products

Chemical structure

BIBF 1202

3D structure

Chemical Properties of BIBF 1202

Cas No. 894783-71-2 SDF Download SDF
PubChem ID 11606145 Appearance Powder
Formula C30H31N5O4 M.Wt 525.6
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 45 mg/mL (85.62 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylic acid
SMILES CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)O)NC3=O)C5=CC=CC=C5
Standard InChIKey KEHNCEDHZGQSNP-DQSJHHFOSA-N
Standard InChI InChI=1S/C30H31N5O4/c1-33-14-16-35(17-15-33)19-26(36)34(2)23-11-9-22(10-12-23)31-28(20-6-4-3-5-7-20)27-24-13-8-21(30(38)39)18-25(24)32-29(27)37/h3-13,18,31H,14-17,19H2,1-2H3,(H,32,37)(H,38,39)/b28-27-
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of BIBF 1202

DescriptionBIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.In Vitro:The major metabolic pathway for BIBF 1120 is methyl ester cleavage to BIBF 1202. Subsequently, the free carboxyl group of BIBF 1202 is glucuronidated to 1-O-acylglucuronide[2].

References:
[1]. Hilberg F, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumorefficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. [2]. Stopfer P, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011 Apr;41(4):297-311.

BIBF 1202 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BIBF 1202 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BIBF 1202

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9026 mL 9.5129 mL 19.0259 mL 38.0518 mL 47.5647 mL
5 mM 0.3805 mL 1.9026 mL 3.8052 mL 7.6104 mL 9.5129 mL
10 mM 0.1903 mL 0.9513 mL 1.9026 mL 3.8052 mL 4.7565 mL
50 mM 0.0381 mL 0.1903 mL 0.3805 mL 0.761 mL 0.9513 mL
100 mM 0.019 mL 0.0951 mL 0.1903 mL 0.3805 mL 0.4756 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on BIBF 1202

IC50: 20–100 nmol/L for VEGFR, PDGFR and FGFR (BIBF 1120)

Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a novel treatment modality in oncology. BIBF 1120 is an indolinone derivative blocking VEGFR, PDGFR and FGFR kinase activity in enzymatic assays. BIBF 1202 is the major in-vivo metabolite of BIBF 1120.

In vitro: BIBF 1120 inhibits mitogen-activated protein kinase and Akt signaling pathways mainly via interacting with VEGF, PDGFR and FGFR in three types of cell contributing to angiogenesis, endothelial cells, pericytes, and smooth muscle cells, leading to the inhibition of cell proliferation (EC50, 10–80 nmol/L) and apoptosis [1].

In vivo: In tumor models tested, including human tumor xenografts growing in nude mice and a syngeneic rat tumor model, BIBF 1120 is proven to be active at well-tolerated doses (25–100 mg/kg daily p.o.), as measured by MRI of tumor perfusion after 3 days, reducing vessel density and vessel integrity after 5 days, and inducing profound growth inhibition [1].

Clinical trials: Patients with locally advanced or metastatic relapsed NSCLC in whom first- or second-line platinum-based chemotherapy failed were randomly allocated to daily 250 mg BIBF 1120 b.i.d. or 150 mg BIBF 1120 b.i.d. Median PFS was 6.9 weeks, with no significant difference between treatment arms. Median overall survival (OS) was 21.9 weeks. BIBF 1120 displayed dose-linear pharmacokinetic characteristics. Continuous treatment with BIBF 1120 was well tolerated, and with no difference in efficacy between treatment arms [2].

References:
[1] Frank Hilberg, Gerald J.  Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant, Armin Heckel, and Wolfgang J. Rettig. BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Cancer Res 2008;68(12):4774–82
[2] Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J.   A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011 Jun;22(6):1374-81.

Featured Products
New Products
 

References on BIBF 1202

Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study.[Pubmed:26342166]

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:239-44.

A sensitive and rapid ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed to simultaneous determine nintedanib and BIBF 1202 in mice plasma and tissue using carbamazepine as the internal standard (IS). Sample preparation was accomplished through a protein precipitation procedure with acetonitrile. The analyte and IS were separated on an Acquity UPLC BEH C18 column (2.1mmx50mm, 1.7mum) with the mobile phase of acetonitrile and 0.1% formic acid in water with gradient elution at a flow rate of 0.40mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer equipped with electrospray ionization (ESI) by multiple reactions monitoring (MRM) of the transitions at m/z 540.3-->113.1 for nintedanib, m/z 526.3-->113.1 for BIBF 1202 and m/z 237.1-->194.1 for IS, respectively. The linearity of this method was found to be within the concentration range of 1-1000ng/mL with a lower limit of quantification of 1.0ng/mL for each drug. Only 3.0min was needed for an analytical run. The inter-day and intra-day precision and accuracy of quality control (QC) samples, evaluated both in plasma and tissue homogenates, were all within 15%. The method was successfully applied to the pharmacokinetic and tissue distribution study of nintedanib and BIBF 1202 in mice after oral administration of nintedanib.

Description

BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.

Keywords:

BIBF 1202,894783-71-2,Natural Products, buy BIBF 1202 , BIBF 1202 supplier , purchase BIBF 1202 , BIBF 1202 cost , BIBF 1202 manufacturer , order BIBF 1202 , high purity BIBF 1202

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: